Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China

Hepatology

Volumn 51, Issue 2, 2010, Pages 405-414

  Hutton, David W ^a   So, Samuel K ^b   Brandeau, Margaret L ^a  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHINA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SENSITIVITY ANALYSIS; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; COST-BENEFIT ANALYSIS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; VACCINATION; YOUNG ADULT;

EID: 75449107955     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23310     Document Type: Article

References (72)

1. Progress in hepatitis B prevention through universal infant vaccination-China, 1997-2006. MMWR Morb Mortal Wkly Rep 2007;56:441-445.
2. World Health Organization. WHO report 2008. Global tuberculosis control-surveillance, planning, financing. Available at: http://www.who.int/tb/ publications/global-report/2008/pdf/annex-3.pdf. Accessed November 18, 2008.
3. World Health Organization. Epidemiological fact sheet on HIV and AIDS: China. Available at: http://www.who.int/globalatlas/predefinedreports/EFS2008/ full/EFS2008-CN.pdf. Accessed November 18, 2008.
4. World Health Organization. WHO Disease and injury country estimates. Available at: http://www.who.int/healthinfo/global-burden-disease/estimates- country/en/index.html. Accessed October 30, 2008.
5. World Health Organization. Malaria annual data. Available at: http://www.wpro.who.int/sites/mvp/data/malaria/2006.htm. Accessed November 18, 2008.
6. Liu J, Fan D. Hepatitis B in China. Lancet 2007;369:1582-1583.
7. Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447-450.
8. The Ministry of Health conference on planning and hepatitis B immunization, malaria prevention and control work [in Chinese]. Available at: http://www.gov.cn/xwfb/2008-04/21/content-950425.htm. Accessed August 1, 2008.
9. United States Census Bureau. China International Database country summary. Available at: http://www.census.gov/ipc/www/idb/country/chportal. html#TAB. Accessed November 18, 2008.
10. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001;10:751-774.
11. Wittet S. Hepatitis B Vaccine Introduction-Lessons Learned in Advocacy, Communication, and Training. Seattle, Washington: Program for Appropriate Technology in Health (PATH), Bill and Melinda Gates Children's Vaccine Program, 2001. Bill and Melinda Gates Children's Vaccine Program Occasional Paper No. 4.
12. World Health Organization. Western Pacific Regional Plan for Hepatitis B Control Through Immunization. Manila, Philippines: World Health Organization; 2007. Report No. (WP)/ICP/EPI/5.2/001-E.
13. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005;142:821-831.
14. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007;147:460-469.
15. Murray CJ, Lopez A. World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization, 2002.
16. International Monetary Fund. World Economic Outlook Database for October 2007 October 17, 2007.
17. World Bank. World Development Indicators database. Available at: http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK: 20394822~isCURL:Y~menuPK:1192694~pagePK:64133150~piPK:64133175~theSitePK:239419, 00.html. Accessed August 1, 2008.
18. Central Intelligence Agency. The World Factbook-China. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/ch.html#Econ. Accessed August 1, 2008.
19. Murray CJL, Salomon JA, Mathers CD, Lopez AD, editors. Summary Measures of Population Health. Concepts, Ethics, Measurement and Applications. Geneva, Switzerland: World Health Organization, 2002.
20. Gong XH, Li YH, Liu LR, Jia L, Xing YL, Wang YQ. Study on the afficacy [sic] of hepatitis B immunization among youngsters in Beijing [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25:388-390.
21. Gong XH, Liu LR, Jia L, Li YH, Xing YL, Wang QY. Epidemiological effect of hepatitis B immunization among newborn babies in Beijing [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003;11:201-202.
22. Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, Iloeje UH. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38(Suppl.):S175-S178.
23. World Health Organization. Hepatitis B. Fact sheet no. 204. Geneva, Switzerland: World Health Organization, 2008.
24. Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin Vaccine Immunol 2006;13:661-664.
25. Alimonos KK, Nafziger AAN, Murray JJ, Bertino JJS. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis 1998;26:566-571.
26. Chen JJ. A model HBV catch-up immunization and education project in Qinghai, China. In: National Immunization Conference 2008. March 17, 2008.
27. People's Daily Online. Chinese, U.S. agencies help hepatitis B prevention in northwest China. Available at: http://english.peopledaily.com.cn/200609/11/ eng20060911-301654.html. Accessed November 18, 2008.
28. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, Lin CY, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26:655-658.
29. Li RC, Yang JY, Gong J, Li YP, Huang ZN, Fang KX, et al. Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25: 385-387.
30. Gong J, Li RC, Yang JY, Li YP, Chen XR, Xu ZY, et al. Long-term efficacy of infant hepatitis B immunization program [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003;11:203-205.
31. Margolis H, Coleman P, Brown R, Mast E, Sheingold S, Arevalo J. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995;274:1201-1208.
32. Pisu M, Meltzer M, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002;21:312-321.
33. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253:197-201.
34. Seeff L, Beebe G, Hoofnagle J, Norman J, Buskell-Bales Z, Waggoner J, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. New Engl J Med 1987;316:965-970.
35. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
36. Chen D, Yao G-b, Chen W. Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B [in Chinese]. Chinese Hepatology 2007;12:164-167.
37. Jacobs R, Saab S, Meyerhoff A. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003;51:227-236.
38. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10:1-200.
39. Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ 2003;81:334-342.
40. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005;192:1720-1726.
41. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005;192(Suppl. 1):S133-S145.
42. Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008;93:52-58.
43. Dai ZC, Qi GM. Viral Hepatitis in China: Seroepidemiological Survey in Chinese Population (Part One) 1992-1995. Beijing, China: Scientific and Technical Documents Publishing House, 1997.
44. State Statistical Bureau of the People's Republic of China. China Statistical Yearbook. English ed. Hong Kong: International Centre for the Advancement of Science & Technology, 2006.
45. Bristol-Myers Squibb Foundation and China Foundation for Hepatitis Prevention and Control collaborate to fight one of China's most pressing health problems. Available at: http://investor.bms.com/phoenix.zhtml?c=106664&p= irol-newsArticle&ID=638504&highlight=. Accessed November 1, 2008.
46. Ho L. Public "lacks awareness" of hepatitis B. Available at: http://www.chinadaily.com.cn/cndy/2007-12/11/content-6311290.htm. Accessed November 1, 2008.
47. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. HEPATOLOGY 1987;7:758-763.
48. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
49. Lin X, Robinson NJ, Thursz M, Rosenberg DM, Weild A, Pimenta JM, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005;20:833-843.
50. Centers for Disease Control and Prevention (CDC). Hepatitis B fact sheet. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm. Accessed April 8, 2008.
51. Chen CJ, Yang HI, Su JUN, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
52. Perrillo R, Hann H, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
53. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
54. Chan HL-Y, Leung NW-Y, Hui AY, Wong VW-S, Liew C-T, Chim AM-L, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-{alpha}2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
55. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24:45-53.
56. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998;5:389-397.
57. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-2137.
58. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-{alpha}2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-865.
59. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
60. Organ Procurement and Transplantation Network. Data. Available at: http://www.optn.org/latestData/viewDataReports.asp. Accessed November 1, 2008.
61. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-237.
62. Yuen M-F, Cheng C-C, Lauder IJ, Lam S-K, Ooi CG, Lai C-L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. HEPATOLOGY 2000;31:330-335.
63. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2005;2006:801-807.
64. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington, DC: Public Health Foundation, 2007.
65. Hu RH, Ho MC, Wu YM, Yu SC, Lee PH. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin Transplant 2005;19:175-180.
66. Pierie JP, Muzikansky A, Tanabe KK, Ott MJ. The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma. Ann Surg Oncol 2005;12:552-560.
67. Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, et al. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience. Transplant Proc 2007;39:153-159.
68. Clements CJ, Baoping Y, Crouch A, Hipgrave D, Mansoor O, Nelson CB, et al. Progress in the control of hepatitis B infection in the Western Pacific region. Vaccine 2006;24:1975-1982.
69. Juan S. China "has 120m hepatitis B carriers." Available at: http://www.chinadaily.com.cn/china/2007-09/01/content-6073020.htm#. Accessed November 1, 2008.
70. UNICEF. 2003 Vaccine projection: quantities and pricing. Available at:http://www.unicef.org/supply/files/2003-vaccine-projection.pdf. Accessed November 18, 2008.
71. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004;38: S136-S143.
72. Lacey L, Tan A. Economic evaluation of different treatments of HBeAgnegative chronic hepatitis B in China [in Chinese]. Chin J Infect Dis 2007;25:473-479.